Table 3.

Report of published RCTs on plazomicin.

Year of Publication	Identification Number	Study Phase	Study Title	Reference (URL)
2021	NCT04699656	Phase 1	Plazomicin Study in ESRD Patients Receiving IHD	https://ClinicalTrials.gov/show/NCT04699656 (accessed on 27 October 2022)
2017	NCT03270553	Phase 1	A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin	https://ClinicalTrials.gov/show/NCT03270553 (accessed on 27 October 2022)
2017	NCT03177278	Phase 1	A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin	https://ClinicalTrials.gov/show/NCT03177278 (accessed on 27 October 2022)
2012	NCT01462136 Published in 2018	Phase 1	PK Study of ACHN-490 Injection in Renally Impaired Subjects	https://ClinicalTrials.gov/show/NCT01462136 (accessed on 27 October 2022)
2012	NCT01514929 Published in 2019	Phase 1	A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers	https://ClinicalTrials.gov/show/NCT01462136 (accessed on 27 October 2022)
2010	NCT01034774	Phase 1	Phase 1 Study to Determine Safety, Blood PK and Lung Penetration	https://ClinicalTrials.gov/show/NCT01034774 (accessed on 27 October 2022)
2009	NCT00822978 Published in 2012	Phase 1	Phase 1 Study for Safety of ACHN-490	https://ClinicalTrials.gov/show/NCT00822978 (accessed on 27 October 2022)
2018	NCT01096849	Phase 2	A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis	https://clinicaltrials.gov/ct2/show/NCT01096849 (accessed on 27 October 2022)
2012	NCT01096849	Phase 2	A Study of Plazomicin Compared with Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)	https://ClinicalTrials.gov/show/NCT01096849 (accessed on 27 October 2022)
2019	NCT01970371 Published in 2018 and 2019	Phase 3	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)	https://ClinicalTrials.gov/show/NCT01970371 (accessed on 27 October 2022)
2019	NCT02486627	Phase 3	Once-Daily Plazomicin for Complicated Urinary Tract Infections	https://ClinicalTrials.gov/show/NCT02486627 (accessed on 27 October 2022)
2017	NCT00676169 Published in 2018 and 2019	Phase 3	Microbiological outcomes with plazomicin (PLZ) versus meropenem (MEM) in patients with complicated urinary tract infections (CUTI), including acute pyelonephritis (AP) in the epic study	https://ClinicalTrials.gov/show/ NCT00676169 (accessed on 27 October 2022)
2016	NCT01970371	Phase 3	A Study of Plazomicin Compared with Colistin in Patients with Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)	https://ClinicalTrials.gov/show/ NCT01970371 (accessed on 27 October 2022)
2016	2015-001588-37	Phase 3	A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Meropenem followed by Optional Oral Therapy for the Treatment of complicated urinary tract infections	https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001588-37 (accessed on 27 October 2022)
2016	2013-001997-18	Phase 3	A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001997-18/results (accessed on 27 October 2022)

Synthesis of the published RCTs on the use of plazomicin in clinical practice. The table describes the year of publication, the identification number of each trial, the title, and the URL where the trial is shown extensively.